Tempus announces multi-year collaboration with Moderna and Merck

TEM•2026-10-07

Tempus announced an expanded multi-year collaboration with Moderna and Merck for intismeran autogene commercialization; financial terms were not disclosed.

1. Collaboration details

Tempus will manage the collection and transfer of tumor tissue and blood samples needed for next-generation sequencing, and provide sequencing services to support intismeran autogene design and manufacturing.

Tempus announces multi-year collaboration with Moderna and Merck

1. Collaboration details

Related News

PJT Partners Inc.: UBS cuts target price to $165 from $176

Lucas GC 1H 2026 net income drops 8% to RMB 19.9 million; revenue falls 37% to RMB 245.3 million

Google launches Playground experimental platform for creating custom games

BRP Inc.: UBS cuts target price to C$86 from C$94

Central Puerto reports buyback totaling AR$ 244.92 million and USD 380,627.57